Regional trends in β-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004

Journal of Infection

Volumn 55, Issue 2, 2007, Pages 111-118

  Felmingham, David ^a   Cantón, Rafael ^b   Jenkins, Stephen G ^c  

^a GR Micro Ltd   (United Kingdom)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial resistance; erm (A); erm (B); erm (TR); Ketolide; Macrolides; mef (A); Multiple resistance; Penicillin; Streptococcus pneumoniae; Telithromycin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFUROXIME; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CANADA; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GEOGRAPHICAL VARIATION (SPECIES); GREECE; METHYLATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PREVALENCE; SOUTH AFRICA; SOUTH KOREA; STREPTOCOCCUS PNEUMONIAE; TREND STUDY; UNITED STATES;

BETA-LACTAM RESISTANCE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; KETOLIDES; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; PREVALENCE; STREPTOCOCCUS PNEUMONIAE; WORLD HEALTH;

EID: 34447125719     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2007.04.006     Document Type: Article

References (34)

1. Niederman M.S., Mandell L.A., Anzueto A., Bass J.B., Broughton W.A., Campbell G.D., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163 (2001) 1730-1754
2. Ball P. Epidemiology of chronic bronchitis and its exacerbations. Chest 108 Suppl. 2 (1995) 43S-52S
3. Anon, Jacobs M.R., Poole M.D., Ambrose P.G., Benninger M.S., Hadley J.A., et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 130 Suppl. 1 (2004) 1-45
4. Felmingham D., and Grüneberg R.N. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 45 (2000) 191-203
5. Hoban D.J., Doern G.V., Fluit A.C., Roussel-Delvallez M., and Jones R.N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 31 Suppl. 2 (2001) S81-S93
6. Felmingham D. The need for antimicrobial resistance surveillance. J Antimicrob Chemother 50 Suppl. 1 (2002) 1-7
7. Karlowsky J.A., Thornsberry C., Critchley I.A., Jones M.E., Evangelista A.T., Noel G.J., et al. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob Agents Chemother 47 (2003) 1790-1797
8. Morrissey I., Robbins M., Viljoen L., and Brown D.F. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods. J Antimicrob Chemother 55 (2005) 200-208
9. Klugman K.P., and Lonks J.R. Hidden epidemic of macrolide-resistant pneumococci. Emerging Infect Dis 11 (2005) 802-807
10. Rzeszutek M., Wierzbowski A., Hoban D.J., Conly J., Bishai W., and Zhanel G.G. A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae. Int J Antimicrob Agents 24 (2004) 95-104
11. Daneman N., McGeer A., Green K., Low D.E., and for the Toronto Invasive Bacterial Diseases Network. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 43 (2006) 432-438
12. Leclercq R., and Couvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 35 (1991) 1267-1272
13. Sutcliffe J. Resistance to macrolides mediated by efflux mechanism. Curr Opin Anti-Infect Investig Drugs 1 (1999) 403-412
14. Corso A., Severina E.P., Petruk V.F., Mauriz Y.R., and Tomasz A. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist 4 (1998) 325-337
15. Farrell D.J., Jenkins S.G., Brown S.D., Patel M., Lavin B.S., and Klugman K.P. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerging Infect Dis 11 (2005) 851-858
16. Jenkins S.G., Farrell D.J., Patel M., and Lavin B.S. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3. J Infect 51 (2005) 355-363
17. Farrell D.J., Morrissey I., Bakker S., Buckridge S., and Felmingham D. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob Agents Chemother 48 (2004) 3169-3171
18. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M07-A7 (2006), CLSI, Wayne, PA
19. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 16th informational supplement, document M100-S16 (2006), CLSI, Wayne, PA
20. Farrell D.J., Morrissey I., Bakker S., and Felmingham D. Detection of macrolide resistance mechanisms in Streptococcus pneumoniae and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization. J Antimicrob Chemother 48 (2001) 541-544
21. Shackcloth J., Williams L., and Farrell D.J. Streptococcus pneumoniae and Streptococcus pyogenes isolated from a paediatric population in Great Britain and Ireland: the in vitro activity of telithromycin versus comparators. J Infect 48 (2004) 229-235
22. Oteo J., Lazaro E., de Abajo F.J., Baquero F., Campos J., and for the Spanish Members of the European Antimicrobial Resistance Surveillance System. Trends in antimicrobial resistance in 1,968 invasive Streptococcus pneumoniae strains isolated in Spanish hospitals (2001 to 2003): decreasing penicillin resistance in children's isolates. J Clin Microbiol 42 (2004) 5571-5577
23. Hsueh P.R. Decreasing rates of resistance to penicillin, but not erythromycin, in Streptococcus pneumoniae after introduction of a policy to restrict antibiotic usage in Taiwan. Clin Microbiol Infect 11 (2005) 925-927
24. Adam D. Global antibiotic resistance in Streptococcus pneumoniae. J Antimicrob Chemother 50 Suppl. (2002) 1-5
25. Bouchillon S.K., Hoban D.J., Johnson J.L., Johnson B.M., Butler D.L., Saunders K.A., et al. In vitro activity of gemifloxacin and contemporary oral antimicrobial agents against 27247 Gram-positive and Gram-negative aerobic isolates: a global surveillance study. Int J Antimicrob Agents 23 (2004) 181-196
26. Felmingham D., White A.R., Jacobs M.R., Appelbaum P.C., Poupard J., and Miller J.A. The Alexander Project: the benefits from a decade of surveillance. J Antimicrob Chemother 56 Suppl. 2 (2005) ii3-ii21
27. Jones M.E., Blosser-Middleton R.S., Thornsberry C., Karlowsky J.A., and Sahm D.F. The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002. Diagn Microbiol Infect Dis 47 (2003) 579-586
28. Shortridge V.D., Doern G.V., Brueggemann A.B., Beyer J.M., and Flamm R.K. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis 29 (1999) 1186-1188
29. Zhanel G.G., Dueck M., Hoban D.J., Vercaigne L.M., Embil J.M., Gin A.S., et al. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 61 (2001) 443-498
30. Schito G.C., Marchese A., Elkharrat D., and Farrell D.J. Comparative activity of telithromycin against macrolide-resistant isolates of Streptococcus pneumoniae: results of two years of the PROTEKT surveillance study. J Chemother 16 (2004) 13-22
31. Farrell D.J., Klugman K.P., and Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 26 (2007) 123-128
32. Kyaw M.H., Lynfield R., Schaffner W., Craig A.S., Hadler J., Reingold A., et al., Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354 (2006) 1455-1463
33. Ekström N., Åhman H., Verho J., Jokinen J., Vakevainen M., Kilpi T., et al. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal vaccines PncCRM and PncOMPC in the Finnish otitis media vaccine trial. Infect Immun 73 (2005) 369-377
34. Beall B., McEllistrem M.C., Gertz Jr. R.E., Wedel S., Boxrud D.J., Gonzalez A.L., et al. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 44 (2006) 999-1017